Skip to main content
S 670 117th Congress Senate Health Advisory bodies Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Executive agency funding and structure Food and Drug Administration (FDA) Health technology, devices, supplies Manufacturing Medical research Research administration and funding

Speeding Therapy Access Today Act of 2021

Introduced: March 10, 2021 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 10, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Mar 10, 2021
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Speeding Therapy Access Today Act of 2021

This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases.

The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies).

The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations.

The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.

What's happening now March 10, 2021

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
  • HR 1730 Identical bill Speeding Therapy Access Today Act of 2021
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1
R
Wicker, Roger F.
Mississippi · Mar 10, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). S. 670: Speeding Therapy Access Today Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-S-670/
MLA
"S. 670: Speeding Therapy Access Today Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-670/.
Bluebook (legal)
S. 670, 117th Cong. (2026), https://openamerica.io/bill/117-S-670/.
Markdown link
[S. 670: Speeding Therapy Access Today Act of 2021](https://openamerica.io/bill/117-S-670/)
Report a problem